A Phase 1 interventional study of Budesonide delayed release tablet 4mg and Budesonide Delayed Release Capsules in IgA Nephropathy (IgAN), sponsored by Triastek, lnc.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by Triastek, lnc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 127 studies in Glomerulonephritis, IGA with a site in China — 58 open to participants now, 73 under way, 20 of them phase 3. Glomerulonephritis, IGA · China.
Among the 127 studies in Glomerulonephritis, IGA with a site in China, this one is the 95th largest by planned enrollment of the 109 interventional ones that give a count, is one of 25 that started in 2026, is one of 21 in phase 1, reaches primary completion later than 28 of the 72 other live ones, and was the 127th registered.
276 studies on the registry are indexed under Glomerulonephritis, IGA; 108 are open to participants now.
Browse Glomerulonephritis, IGA studies →58 of the 127 studies in Glomerulonephritis, IGA with a site in China are open now. Recruiting first, the newest first:
Hong Zhang · Sites in China
Ages 18–75
Novartis Pharmaceuticals · Sites in China, United States, Colombia and 5 more countries
Ages 2–18
Chengdu Suncadia Medicine Co., Ltd. · Sites in China
Ages 18+
Nanfang Hospital, Southern Medical University · Sites in China
Ages 18–75
ADARx Pharmaceuticals, Inc. · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 68 Glomerulonephritis, IGA studies recruiting now, 39 (57%) set no upper age limit and 24 (35%) stop at 75 or younger; 21 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
127 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 34 · Phase 3 27 · Phase 4 15
First in 2002; this study’s year is marked. 25 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 18 is below the median of 62 across 221 interventional studies indexed under Glomerulonephritis, IGA.
Median enrollment 84 across the 109 interventional studies, 537 across the 18 observational. Of the 35 that completed or were terminated, 4 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
57 of 127 have an industry lead sponsor. The 10 most frequent:
Triastek, lnc. is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Triastek, lnc. has 2 studies filed under Glomerulonephritis, IGA — fewer than ten, so there is no comparison to draw.
22 of the studies in Glomerulonephritis, IGA with a site in China that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06819826Phase 3Biocity Biopharmaceutics Co., Ltd.A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria | 2026-12-31 |
| NCT06935357Phase 3BiogenA Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) | 2027-05-31 |
| NCT05852938Phase 3Novartis PharmaceuticalsA Study of Zigakibart in Adults With IgA Nephropathy | 2027-08-10 |
| NCT07014826Phase 3Chengdu Suncadia Medicine Co., Ltd.A Trial of HRS-5965 Capsule in Primary IgA Nephropathy | 2027-10 |
| NCT02954419Sun Yat-sen UniversityIgA Nephropathy Biomarkers Evaluation Study (INTEREST) | 2026-11 |
Add all 22 to your calendar (.ics) → With an account.
Among the 127 studies in Glomerulonephritis, IGA with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to evaluate the PK characteristics and relative bioavailability of single oral doses of Budesonide Delayed Release Tablet and Budesonide Delayed Release Capsules in healthy participants, and to compare the formulation similarity of Budesonide Delayed Release Tablet T1 and T2. The main questions it aims to answer are:
How do the pharmacokinetic (PK) characteristics and relative bioavailability of Budesonide Delayed Release Tablet T1 (strength: 4 mg) compare with those of Budesonide Delayed Release Capsules R (trade name: Nefecon, strength: 4 mg)? How do the PK characteristics and relative bioavailability of Budesonide Delayed Release Tablet T2 (strength: 16 mg) compare with those of Budesonide Delayed Release Capsules R (trade name: Nefecon, strength: 4 mg)? How similar are the formulations of Budesonide Delayed Release Tablet T1 (strength: 4 mg) and T2 (strength: 16 mg), and how do their relative bioavailabilities compare? Researchers will compare Budesonide Delayed Release Tablet T1 (strength: 4 mg) and T2 (strength: 16 mg) to Budesonide Delayed Release Capsules R (trade name: Nefecon, strength: 4 mg) to see if the tablets work to treat primary immunoglobulin A nephropathy (IgAN).
Participants will:
Take a single oral dose of Budesonide Delayed Release Tablet T1 (16 mg, given as 4 mg/tablet × 4 tablets), Tablet T2 (16 mg, given as 16 mg/tablet × 1 tablet), or Capsules R (16 mg, given as 4 mg/capsule × 4 capsules) as directed Visit the clinic regularly for checkups and tests Report any medical problems they experience while taking the study drug
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
1 . Fully understand the purpose, nature, procedures of the study and possible adverse reactions, voluntarily participate in the study, and sign the form (ICF) before any study procedures begin; 2. Healthy male or female participants aged ≥18 years; 3. Male weight ≥ 50.0 kg, female weight ≥ 45.0 kg; (BMI) in the range of 18.5 to 24.9 kg/m2 (inclusive); 4. Participants voluntarily agree to use effective during the study and for 3 months after the last dose, and have no plans to conceive or father a child, donate sperm, or donate eggs during that period; 5. Able to communicate well with the investigator and understand and comply with all requirements of this study.
Exclusion Criteria:
Be unsuitable for enrollment or other situations where the participant is unable to participate for personal reasons as judged by the investigator.
Female participants who meet the following conditions, in addition to the above requirements, should also be excluded:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Budesonide delayed release tablet 4mg · Drug: Budesonide Delayed Release Capsules · Drug: Budesonide delayed release tablet 16mg
Drug: Budesonide delayed release tablet 4mg · Drug: Budesonide Delayed Release Capsules · Drug: Budesonide delayed release tablet 16mg
Drug: Budesonide delayed release tablet 4mg · Drug: Budesonide Delayed Release Capsules · Drug: Budesonide delayed release tablet 16mg
Test drug T1
Reference drug
Test drug T2
Cmax
Primary PK parameters
Time frame: up to 48 hours post-dose
AUC4-t
Primary PK parameters
Time frame: up to 48 hours post-dose
AUC0-t
Primary PK parameters
Time frame: up to 48 hours post-dose
AUC0-∞
Primary PK parameters
Time frame: up to 48 hours post-dose
Tmax
Secondary PK parameters
Time frame: up to 48 hours post-dose
Tlag
Secondary PK parameters
Time frame: up to 48 hours post-dose
AUC0-4
Secondary PK parameters
Time frame: up to 4 hours post-dose
t1/2
Secondary PK parameters
Time frame: up to 48 hours post-dose
λz
Secondary PK parameters
Time frame: up to 48 hours post-dose
AUC %Extrap
Secondary PK parameters
Time frame: up to 48 hours post-dose
CL/F
Secondary PK parameters
Time frame: up to 48 hours post-dose
VZ/F
Secondary PK parameters
Time frame: up to 48 hours post-dose
Incidence of adverse events (AEs)
Time frame: Through study completion, an average of 13 days
Plan to share: Undecided
No publications or documents are linked to this record.
Started Nov 2026 (actual). Primary completion is estimated for Jan 2027, 2 months after the start.
Of 22 phase 1 interventional studies under Glomerulonephritis, IGA, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 13. This study's planned 2 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Triastek, lnc.